Expanding Immunotherapy in Early-Stage HR+ and TNBC

Dr Hope Rugo explores how new data suggest immunotherapy could reshape the standard of care for early-stage HR+ and triple-negative breast cancers. Medscape Oncology

Read the full article on medscape.com